After Years Of Setbacks, Marinus Closes In On Rare Epilepsy Opportunity

Ganaxolone Potential In Numerous Rare Conditions

After multiple failed attempts to treat rare conditions, Marinus is on the cusp of success with ganaxolone in genetic epilepsy, and has secured a new European partner in Orion.

Epilepsy brain
CDKL5 deficiency disorder (CDD) is a severe genetic form of epilepsy which can strike within the first three months of life. • Source: Alamy

After 18 years of setbacks and disappointments, Marinus Pharmaceuticals has submitted to the US Food and Drug Administration its candidate ganaxolone to treat a rare genetic form of epilepsy.

Established back in 2003, the company has just one drug candidate, GABA-A modulator ganaxolone, and over the years has seen...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip